Compugen drug effective vs. type I diabetes animal model

|About: Compugen Ltd. (CGEN)|By:, SA News Editor

Compugen (CGEN) +4.8% premarket after announcing a study of its CGEN-15001 Fc fusion protein drug candidate demonstrated high effectiveness in an animal model of autoimmune type I diabetes.

The study suggests the drug turns off the autoimmune process and may potentially lead to restoration of immune tolerance and resolution of autoimmunity, arresting disease progression.